Nu Skin Enter Financials
This page shows Nu Skin Enter (NUS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Earnings swung wildly, but cash generation stayed positive as Nu Skin resized its cost base and reduced debt.
The biggest shift is in earnings quality: net income swung from-$146.6M in FY2024 to$160.2M in FY2025. Operating cash flow told a steadier story, slipping from$111.7M to$80.3M , which suggests the profit rebound was amplified by non-cash or below-operating items rather than by a full sales recovery.
Core product economics held up better than revenue: sales fell again in FY2025, yet gross margin stayed near
Working capital and leverage both improved: inventory dropped from
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Nu Skin Enter's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Nu Skin Enter has an operating margin of 4.4%, meaning the company retains $4 of operating profit per $100 of revenue. This below-average margin results in a low score of 19/100, suggesting thin profitability after operating expenses. This is up from -8.8% the prior year.
Nu Skin Enter's revenue declined 14.3% year-over-year, from $1.7B to $1.5B. This contraction results in a growth score of 8/100.
Nu Skin Enter carries a low D/E ratio of 0.25, meaning only $0.25 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 93/100, indicating a strong balance sheet with room for future borrowing.
Nu Skin Enter's current ratio of 2.08 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.
Nu Skin Enter has a free cash flow margin of 3.1%, earning a moderate score of 41/100. The company generates positive cash flow after capital investments, but with room for improvement.
Nu Skin Enter's ROE of 19.9% shows moderate profitability relative to equity, earning a score of 30/100. This is up from -22.5% the prior year.
Nu Skin Enter scores 3.56, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Nu Skin Enter passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, all 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Nu Skin Enter generates $0.50 in operating cash flow ($80.3M OCF vs $160.2M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Nu Skin Enter earns $4.7 in operating income for every $1 of interest expense ($65.8M vs $13.9M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Earnings & Revenue
Nu Skin Enter generated $1.5B in revenue in fiscal year 2025. This represents a decrease of 14.3% from the prior year.
Nu Skin Enter's EBITDA was $118.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 244.3% from the prior year.
Nu Skin Enter reported $160.2M in net income in fiscal year 2025. This represents an increase of 209.3% from the prior year.
Nu Skin Enter earned $3.18 per diluted share (EPS) in fiscal year 2025. This represents an increase of 207.8% from the prior year.
Cash & Balance Sheet
Nu Skin Enter generated $46.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 34.4% from the prior year.
Nu Skin Enter held $238.6M in cash against $204.2M in long-term debt as of fiscal year 2025.
Nu Skin Enter had 48M shares outstanding in fiscal year 2025. This represents a decrease of 3.2% from the prior year.
Margins & Returns
Nu Skin Enter's gross margin was 69.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.
Nu Skin Enter's operating margin was 4.4% in fiscal year 2025, reflecting core business profitability. This is up 13.2 percentage points from the prior year.
Nu Skin Enter's net profit margin was 10.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 19.3 percentage points from the prior year.
Nu Skin Enter's ROE was 19.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 42.4 percentage points from the prior year.
Capital Allocation
Nu Skin Enter invested $10.8M in research and development in fiscal year 2025. This represents a decrease of 16.9% from the prior year.
Nu Skin Enter spent $20.0M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
Nu Skin Enter invested $34.3M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 17.6% from the prior year.
NUS Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $320.6M-13.4% | $370.3M+1.7% | $364.2M-5.7% | $386.1M+5.9% | $364.5M-18.2% | $445.6M+3.6% | $430.1M-2.0% | $439.1M |
| Cost of Revenue | $106.1M-2.0% | $108.3M+0.8% | $107.5M-10.7% | $120.4M+2.4% | $117.5M-29.4% | $166.4M+29.3% | $128.7M-2.4% | $131.9M |
| Gross Profit | $214.5M-18.1% | $262.0M+2.0% | $256.7M-3.4% | $265.7M+7.6% | $247.0M-11.5% | $279.1M-7.4% | $301.5M-1.9% | $307.2M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $98.5M-8.2% | $107.4M+2.5% | $104.8M-1.8% | $106.7M-5.7% | $113.2M-6.4% | $120.9M+4.6% | $115.6M-2.0% | $117.9M |
| Operating Income | $4.0M-82.7% | $23.2M+7.4% | $21.6M-29.7% | $30.8M+410.8% | -$9.9M+81.3% | -$53.1M-391.2% | $18.2M+114.5% | -$125.6M |
| Interest Expense | $4.3M+6.4% | $4.0M-3.6% | $4.1M+64.1% | $2.5M-23.1% | $3.3M-44.0% | $5.9M-9.8% | $6.5M-3.3% | $6.7M |
| Income Tax | $763K-79.4% | $3.7M+441.0% | -$1.1M-117.2% | $6.3M-76.8% | $27.1M+224.8% | -$21.7M-534.3% | $5.0M+137.3% | -$13.4M |
| Net Income | $1.8M-87.3% | $14.5M-15.2% | $17.1M-19.1% | $21.1M-80.4% | $107.5M+397.8% | -$36.1M-534.9% | $8.3M+107.0% | -$118.3M |
| EPS (Diluted) | $0.04 | N/A | $0.34-20.9% | $0.43-79.9% | $2.14 | N/A | $0.17+107.1% | $-2.38 |
NUS Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B-2.0% | $1.4B-1.3% | $1.4B-1.3% | $1.4B+3.8% | $1.4B-5.3% | $1.5B-7.2% | $1.6B-0.2% | $1.6B |
| Current Assets | $522.9M-4.5% | $547.7M-0.1% | $548.1M-4.1% | $571.6M+8.9% | $524.9M-2.6% | $538.6M-17.6% | $653.4M-0.2% | $654.4M |
| Cash & Equivalents | $198.7M-16.8% | $238.6M-5.2% | $251.8M-4.7% | $264.2M+29.6% | $203.8M+9.0% | $186.9M-17.9% | $227.8M+1.6% | $224.3M |
| Inventory | $178.6M0.0% | $178.6M+0.1% | $178.5M-1.0% | $180.4M-4.4% | $188.8M-0.8% | $190.2M-23.2% | $247.8M+1.6% | $244.0M |
| Accounts Receivable | $45.0M+13.8% | $39.5M-19.1% | $48.9M-18.1% | $59.7M+5.5% | $56.6M+11.4% | $50.8M-26.2% | $68.8M-3.8% | $71.6M |
| Goodwill | $83.6M0.0% | $83.6M0.0% | $83.6M0.0% | $83.6M0.0% | $83.6M0.0% | $83.6M-16.3% | $99.9M0.0% | $99.9M |
| Total Liabilities | $582.7M-2.9% | $600.1M-3.9% | $624.6M-4.8% | $655.9M+2.9% | $637.4M-22.0% | $817.5M-6.7% | $876.0M-2.6% | $899.8M |
| Current Liabilities | $257.0M-2.6% | $263.7M+3.7% | $254.4M-10.4% | $283.9M+9.1% | $260.3M-12.2% | $296.6M-12.6% | $339.4M+10.0% | $308.6M |
| Long-Term Debt | $203.6M-0.3% | $204.2M-2.3% | $209.0M-2.3% | $213.9M-2.2% | $218.8M-39.8% | $363.6M-2.6% | $373.5M-12.8% | $428.3M |
| Total Equity | $794.1M-1.4% | $805.2M+0.7% | $799.8M+1.5% | $787.8M+4.5% | $754.0M+15.7% | $651.5M-7.8% | $706.9M+3.0% | $686.2M |
| Retained Earnings | $1.9B-0.1% | $1.9B+0.6% | $1.8B+0.8% | $1.8B+1.0% | $1.8B+6.1% | $1.7B-2.2% | $1.8B+0.3% | $1.7B |
NUS Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9M-123.6% | $16.6M-39.5% | $27.5M-23.2% | $35.8M+9101.8% | $389K-98.5% | $25.8M-18.0% | $31.4M-38.6% | $51.2M |
| Capital Expenditures | $13.7M+27.5% | $10.8M+8.5% | $9.9M+54983.3% | $18K-99.9% | $13.6M+8.0% | $12.6M+46.4% | $8.6M+5.8% | $8.1M |
| Free Cash Flow | -$17.6M-400.9% | $5.9M-66.6% | $17.6M-50.9% | $35.8M+371.1% | -$13.2M-199.9% | $13.2M-42.2% | $22.8M-47.0% | $43.1M |
| Investing Cash Flow | -$14.3M-46.4% | -$9.8M+1.6% | -$9.9M-212.8% | $8.8M-95.2% | $181.5M+1432.7% | -$13.6M-108.1% | -$6.5M+23.3% | -$8.5M |
| Financing Cash Flow | -$20.4M-10.3% | -$18.5M+31.2% | -$26.9M-390.0% | $9.3M+105.6% | -$166.3M-281.2% | -$43.6M-51.6% | -$28.8M+0.1% | -$28.8M |
| Dividends Paid | $2.9M-1.1% | $2.9M-1.9% | $3.0M-0.1% | $3.0M-1.3% | $3.0M+0.6% | $3.0M0.0% | $3.0M0.0% | $3.0M |
| Share Buybacks | $5.0M-50.0% | $10.0M+100.1% | $5.0M | $0-100.0% | $5.0M | $0 | $0 | $0 |
NUS Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 66.9%-3.8pp | 70.7%+0.3pp | 70.5%+1.7pp | 68.8%+1.1pp | 67.8%+5.1pp | 62.6%-7.4pp | 70.1%+0.1pp | 70.0% |
| Operating Margin | 1.3%-5.0pp | 6.3%+0.3pp | 5.9%-2.0pp | 8.0%+10.7pp | -2.7%+9.2pp | -11.9%-16.2pp | 4.2%+32.8pp | -28.6% |
| Net Margin | 0.6%-3.3pp | 3.9%-0.8pp | 4.7%-0.8pp | 5.5%-24.0pp | 29.5%+37.6pp | -8.1%-10.0pp | 1.9%+28.9pp | -26.9% |
| Return on Equity | 0.2%-1.6pp | 1.8%-0.3pp | 2.1%-0.5pp | 2.7%-11.6pp | 14.3%+19.8pp | -5.5%-6.7pp | 1.2%+18.4pp | -17.2% |
| Return on Assets | 0.1%-0.9pp | 1.0%-0.2pp | 1.2%-0.3pp | 1.5%-6.3pp | 7.7%+10.2pp | -2.5%-3.0pp | 0.5%+8.0pp | -7.5% |
| Current Ratio | 2.03-0.0 | 2.08-0.1 | 2.15+0.1 | 2.010.0 | 2.02+0.2 | 1.82-0.1 | 1.93-0.2 | 2.12 |
| Debt-to-Equity | 0.260.0 | 0.250.0 | 0.26-0.0 | 0.27-0.0 | 0.29-0.3 | 0.56+0.0 | 0.53-0.1 | 0.62 |
| FCF Margin | -5.5%-7.1pp | 1.6%-3.2pp | 4.8%-4.5pp | 9.3%+12.9pp | -3.6%-6.6pp | 3.0%-2.4pp | 5.3%-4.5pp | 9.8% |
Similar Companies
Frequently Asked Questions
What is Nu Skin Enter's annual revenue?
Nu Skin Enter (NUS) reported $1.5B in total revenue for fiscal year 2025. This represents a -14.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Nu Skin Enter's revenue growing?
Nu Skin Enter (NUS) revenue declined by 14.3% year-over-year, from $1.7B to $1.5B in fiscal year 2025.
Is Nu Skin Enter profitable?
Yes, Nu Skin Enter (NUS) reported a net income of $160.2M in fiscal year 2025, with a net profit margin of 10.8%.
What is Nu Skin Enter's EBITDA?
Nu Skin Enter (NUS) had EBITDA of $118.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Nu Skin Enter have?
As of fiscal year 2025, Nu Skin Enter (NUS) had $238.6M in cash and equivalents against $204.2M in long-term debt.
What is Nu Skin Enter's gross margin?
Nu Skin Enter (NUS) had a gross margin of 69.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Nu Skin Enter's operating margin?
Nu Skin Enter (NUS) had an operating margin of 4.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Nu Skin Enter's net profit margin?
Nu Skin Enter (NUS) had a net profit margin of 10.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Nu Skin Enter's return on equity (ROE)?
Nu Skin Enter (NUS) has a return on equity of 19.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Nu Skin Enter's free cash flow?
Nu Skin Enter (NUS) generated $46.0M in free cash flow during fiscal year 2025. This represents a -34.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Nu Skin Enter's operating cash flow?
Nu Skin Enter (NUS) generated $80.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Nu Skin Enter's total assets?
Nu Skin Enter (NUS) had $1.4B in total assets as of fiscal year 2025, including both current and long-term assets.
What are Nu Skin Enter's capital expenditures?
Nu Skin Enter (NUS) invested $34.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Nu Skin Enter spend on research and development?
Nu Skin Enter (NUS) invested $10.8M in research and development during fiscal year 2025.
What is Nu Skin Enter's current ratio?
Nu Skin Enter (NUS) had a current ratio of 2.08 as of fiscal year 2025, which is generally considered healthy.
What is Nu Skin Enter's debt-to-equity ratio?
Nu Skin Enter (NUS) had a debt-to-equity ratio of 0.25 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Nu Skin Enter's return on assets (ROA)?
Nu Skin Enter (NUS) had a return on assets of 11.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Nu Skin Enter's Altman Z-Score?
Nu Skin Enter (NUS) has an Altman Z-Score of 3.56, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Nu Skin Enter's Piotroski F-Score?
Nu Skin Enter (NUS) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Nu Skin Enter's earnings high quality?
Nu Skin Enter (NUS) has an earnings quality ratio of 0.50x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Nu Skin Enter cover its interest payments?
Nu Skin Enter (NUS) has an interest coverage ratio of 4.7x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Nu Skin Enter?
Nu Skin Enter (NUS) scores 42 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.